Pulmonary and Respiratory Care for Seniors: COPD, Asthma, and Breathing Support

Pulmonary and respiratory care for older adults addresses the diagnosis, monitoring, and management of lung and airway conditions that disproportionately affect adults aged 65 and older. Conditions including chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, and sleep-related breathing disorders represent a leading burden of morbidity in this population. This page covers the major respiratory diagnoses encountered in senior care settings, how clinical management frameworks are structured, the scenarios in which different levels of intervention apply, and the boundaries that distinguish primary care oversight from specialist pulmonology. Understanding these boundaries is directly relevant to chronic disease management for seniors and informs decisions about appropriate care coordination.

Definition and scope

Pulmonary and respiratory care encompasses the evaluation and treatment of conditions affecting the lungs, bronchial airways, diaphragm, and the respiratory control systems governed by the central nervous system. In geriatric populations, lung function declines measurably with age: spirometry reference values published by the Global Lung Function Initiative (GLI) account for age-related reductions in forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) — the two primary metrics used to classify obstruction and restriction.

The primary diagnostic categories relevant to senior respiratory care include:

1. Chronic Obstructive Pulmonary Disease (COPD) — characterized by persistent, incompletely reversible airflow limitation, typically from emphysema, chronic bronchitis, or a combination. COPD is staged using the GOLD (Global Initiative for Chronic Obstructive Lung Disease) classification system, with grades 1 through 4 reflecting increasing severity based on post-bronchodilator FEV₁.
2. Asthma — variable and reversible airflow obstruction, distinguished from COPD by bronchodilator reversibility and the absence of fixed airflow limitation in most cases. The National Asthma Education and Prevention Program (NAEPP), coordinated through the National Heart, Lung, and Blood Institute (NHLBI), provides the foundational clinical guideline in the United States.
3. Pulmonary Fibrosis and Interstitial Lung Disease (ILD) — restrictive patterns on spirometry, identified by reduced FVC with a preserved or elevated FEV₁/FVC ratio, requiring high-resolution CT imaging for subclassification.
4. Obstructive Sleep Apnea (OSA) — upper airway collapse during sleep, measured via the apnea-hypopnea index (AHI) and managed with positive airway pressure therapy, referenced under senior sleep disorder services.
5. Pulmonary Hypertension — elevated mean pulmonary arterial pressure frequently co-occurring with both COPD and cardiac disease, relevant to senior cardiology services.

Respiratory medications fall under FDA-regulated drug categories including short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), anticholinergic bronchodilators, and combination formulations. Oxygen therapy delivery systems are governed by Medicare's Durable Medical Equipment (DME) benefit under 42 C.F.R. Part 410 (CMS, eCFR).

How it works

Respiratory care in older adults follows a tiered evaluation and management structure:

1. Baseline assessment — Spirometry establishes lung function. Pulse oximetry provides a non-invasive measure of oxygen saturation (SpO₂). A resting SpO₂ of 88% or below is the Medicare threshold for qualifying for supplemental oxygen under the DME benefit (CMS Local Coverage Determination policies).
2. Stratification — COPD patients are classified using both GOLD spirometric grades (1–4) and the GOLD ABCD symptom/exacerbation risk groups, which guide pharmacotherapy escalation.
3. Pharmacotherapy — NHLBI's NAEPP guidelines for asthma use a stepwise approach (Steps 1–6) based on symptom frequency, nighttime awakenings, and rescue inhaler use. GOLD guidelines use a parallel stepwise bronchodilator and anti-inflammatory escalation pathway for COPD.
4. Pulmonary rehabilitation — A structured program combining supervised exercise training, education, and behavioral support. The American Thoracic Society (ATS) and the European Respiratory Society (ERS) define pulmonary rehabilitation criteria and outcome metrics. Medicare covers pulmonary rehabilitation for COPD patients meeting specific FEV₁ thresholds under 42 C.F.R. § 410.47.
5. Acute exacerbation management — Exacerbations of COPD (AECOPD) are categorized as mild, moderate, or severe. Severe exacerbations requiring hospitalization involve systemic corticosteroids, short-acting bronchodilators, and in select cases, non-invasive ventilation (NIV) such as bilevel positive airway pressure (BiPAP).
6. Long-term oxygen therapy (LTOT) — Indicated when resting SpO₂ meets CMS criteria; ATS guidelines recommend at least 15 hours per day of oxygen use to produce documented clinical benefit in qualifying patients.

Inhaler technique is a significant compliance variable in older adults. Cognitive and physical limitations — including reduced hand strength and inspiratory flow rates — affect device selection. Spacer devices, breath-actuated inhalers, and soft-mist inhalers are classified alternatives to standard metered-dose inhalers (MDIs). Senior medication management frameworks frequently address inhaler technique assessment as a distinct review component.

Common scenarios

COPD with acute exacerbation — An older adult with known GOLD Grade 2 COPD presents with increased dyspnea, sputum production, and SpO₂ dropping to 86% on room air. Exacerbation triggers include respiratory infections (bacterial or viral), air quality events, and medication non-adherence. Management proceeds through bronchodilator intensification, short-course systemic corticosteroids (typically 5 days per GOLD guidelines), and assessment for antibiotic therapy when bacterial etiology is suspected.

Late-onset or underdiagnosed asthma — Asthma diagnosed after age 65 is often missed because dyspnea is attributed to cardiac causes or deconditioning. Spirometry with bronchodilator reversibility testing differentiates asthma from fixed COPD obstruction. A post-bronchodilator FEV₁ improvement of ≥12% and ≥200 mL is the standard reversibility criterion per NAEPP.

Asthma-COPD overlap (ACO) — Patients exhibiting features of both conditions — typically a history of atopy or childhood asthma alongside a smoking history — present a distinct management challenge. Neither GOLD nor NAEPP guidelines fully address ACO, and specialist pulmonology referral is generally indicated.

Post-COVID respiratory sequelae — Older adults who experienced moderate-to-severe COVID-19 illness may have persistent reduced diffusion capacity (DLCO) or fibrotic changes detectable on CT imaging. These patients require pulmonary function testing follow-up outside routine COPD or asthma management pathways.

Palliative breathlessness management — In advanced COPD or pulmonary fibrosis, refractory dyspnea becomes a primary symptom burden. Opioid-based dyspnea management and goals-of-care conversations intersect with hospice and palliative care for seniors and advance care planning.

Decision boundaries

Distinguishing the appropriate level of care and provider specialty in senior pulmonary management depends on several structural criteria:

Primary care vs. pulmonology specialist referral

Inpatient vs. outpatient threshold — COPD exacerbation severity scoring tools, including the DECAF (Dyspnea, Eosinopenia, Consolidation, Acidemia, Atrial Fibrillation) score, assist in distinguishing patients who can be managed in an outpatient or observation setting from those requiring inpatient admission and monitoring.

Oxygen therapy qualification — Medicare DME coverage for home oxygen requires documented SpO₂ ≤88% at rest, or ≤89% with evidence of specific comorbid conditions, per CMS coverage criteria under the National Coverage Determination for Home Use of Oxygen (CMS NCD 240.2). Physician certification and a face-to-face encounter are required.

Ventilatory support boundaries — NIV (BiPAP) may be initiated in hospital settings for acute hypercapnic respiratory failure. Home